News & Updates

Long-term treatment with secukinumab, either at low or high dose, results in sustained efficacy and better health-related quality of life up to 4 years in children and adolescents with moderate-to-severe chronic plaque psoriasis, as shown in a phase III study presented at EADV 2024.

Ileus and pneumonia occur more frequently than previously reported among individuals with schizophrenia treated with clozapine, reveals a recent study, noting that such conditions also contribute to increased mortality.

The use of menopausal hormone therapy (MHT) can provide protection against psychosis relapse among women of menopausal age with schizophrenia or schizoaffective disorder (SSD), a study has shown.

In a preplanned interim analysis of the NIAGARA trial, the addition of durvalumab to neoadjuvant chemotherapy prior to radical cystectomy (RC) and durvalumab monotherapy following surgery confers a survival advantage over chemo alone for muscle-invasive bladder cancer (MIBC).

Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).

In the management of severe cancer pain, intravenous patient-controlled analgesia (PCA) with hydromorphone delivers superior pain control with greater patient satisfaction as compared with conventional oral morphine, according to the phase III open-label SYLT-021 study.